US Broker Ratings

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Analyst Ratings Signal 105% Potential Upside

Organogenesis Holdings Inc. (NASDAQ: ORGO), a regenerative medicine company specializing in advanced wound care and surgical products, presents a compelling investment opportunity with significant potential upside. Analysts have set an..

ATAI Life Sciences N.V. (ATAI) Stock Analysis: A Biotech Giant with 179% Upside Potential

ATAI Life Sciences N.V. (NASDAQ: ATAI) presents a compelling narrative for investors seeking opportunities in the burgeoning field of mental health treatment biotechnology. Headquartered in Amstelveen, the Netherlands, ATAI is..

Community Health Systems, Inc. (CYH) Stock Analysis: Evaluating a 5.6% Upside Potential in the Healthcare Sector

Community Health Systems, Inc. (NYSE: CYH) operates within the healthcare sector, specifically in the medical care facilities industry in the United States. With a market capitalization of approximately $512.52 million,..

Fulgent Genetics, Inc. (FLGT): Investor Outlook Reveals a 13.55% Potential Upside in the Diagnostics & Research Sector

Fulgent Genetics, Inc. (NASDAQ: FLGT) is a prominent player in the healthcare sector, offering innovative solutions in the diagnostics and research industry. Headquartered in El Monte, California, Fulgent Genetics has..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: Navigating Challenges with a Focus on Revenue Growth

Investors with an interest in the healthcare sector, particularly those focused on medical care facilities, may find Sonida Senior Living, Inc. (NYSE: SNDA) to be a company of interest. Based..

Upstream Bio, Inc. (UPB) Stock Analysis: A 110% Potential Upside with Strong Buy Ratings

Investors with an eye on the biotechnology sector should take a close look at Upstream Bio, Inc. (UPB), a clinical-stage company focused on developing treatments for severe respiratory disorders. With..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Eyeing a 31% Upside Potential for Strategic Investors

Emergent BioSolutions Inc. (NYSE: EBS) finds itself at a pivotal juncture, presenting intriguing opportunities for investors keen on the healthcare sector. As a prominent player in the drug manufacturing industry,..

COMPASS Pathways Plc (CMPS) Stock Analysis: Is a 182% Upside in Reach for This Biotech Pioneer?

COMPASS Pathways Plc (NASDAQ: CMPS) is capturing the attention of investors with its pioneering approach to mental health treatment through innovative psilocybin therapies. As a part of the dynamic healthcare..

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Unveiling a 214% Potential Upside

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) stands at a pivotal moment in its journey within the biotechnology sector, promising transformative innovations in the field of retinal disease therapeutics. With a market..

Opthea Limited (OPT) Stock Analysis: Navigating the Biotech Landscape with a -70.67% Potential Downside

Opthea Limited (OPT), a clinical-stage biopharmaceutical company headquartered in Melbourne, Australia, stands at a pivotal point in its development journey as it focuses on expanding its therapeutic portfolio within the..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Unveiling a Potential 494% Upside in Biotech

Anavex Life Sciences Corp. (NASDAQ: AVXL) has emerged as a compelling player in the biotechnology sector, offering innovative treatments for complex neurodegenerative and neurodevelopmental disorders. With a market capitalization of..

Tourmaline Bio, Inc. (TRML) Stock Analysis: Navigating the Biotech Sector with Limited Upside

Tourmaline Bio, Inc. (NASDAQ: TRML) has emerged as a notable player in the biotechnology sector, focusing on developing treatments for immune and inflammatory diseases. Despite its promising pipeline, the company’s..

Prothena Corporation plc (PRTA): A Biotech Play with a Potential 63.69% Upside

Prothena Corporation plc (NASDAQ: PRTA), a biotechnology company headquartered in Dublin, Ireland, stands at the forefront of innovative therapies targeting diseases related to protein dysregulation. With a current market cap..

Precigen, Inc. (PGEN) Stock Analysis: A Biotech with a 110% Upside Potential

Investors with an eye on the biotechnology sector might want to take a closer look at Precigen, Inc. (NASDAQ: PGEN). With a market capitalization of $1.38 billion, this healthcare gem..

Neuropace, Inc. (NPCE) Stock Analysis: Strong Buy Ratings and 31% Upside Potential

Neuropace, Inc. (NASDAQ: NPCE), a key player in the medical devices industry, is attracting significant attention from investors due to its innovative solutions in treating drug-resistant focal epilepsy. Founded in..

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Exploring a Potential 228% Upside with Innovative Biotech Solutions

Capricor Therapeutics, Inc. (NASDAQ: CAPR) stands as a compelling player in the biotechnology sector, focusing on pioneering therapies for Duchenne muscular dystrophy (DMD) and other critical unmet medical needs. With..

Oruka Therapeutics, Inc. (ORKA): Investor Outlook with a 57% Potential Upside in the Biotechnology Arena

Oruka Therapeutics, Inc. (ORKA) stands out in the biotechnology sector as a clinical-stage biopharmaceutical company making significant strides in developing innovative monoclonal antibody therapeutics. With a market capitalization of $1.37..

Semler Scientific, Inc. (SMLR) Investor Outlook: Targeting a 174% Upside Potential in the Healthcare Sector

In the dynamic world of healthcare, Semler Scientific, Inc. (NASDAQ: SMLR) stands as a noteworthy player, offering innovative solutions to medical professionals across the United States. With its flagship product,..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenges and Opportunities in Biotechnology

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a prominent name within the biotechnology industry, operating at the intersection of healthcare and technology with a focus on cell programming. Headquartered in..

MeiraGTx Holdings plc (MGTX) Stock Analysis: Exploring a Potential 227.84% Upside in the Biotech Sector

For investors with a keen eye on the biotechnology sector, MeiraGTx Holdings plc (NASDAQ: MGTX) presents a compelling opportunity, boasting a potential upside of 227.84%. Specializing in gene therapy treatments,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds